12-2SSS Omalizumab Plus Immunotherapy

Wednesday, 7 December 2011: 11:10 - 11:30
Gran Cancún 5 (Cancún Center)
• Omalizumab and Immunotherapy.pdf

Mario Morais de Almeida , Immunoallergy Department - CUF Descobertas Hospital, Head of Department, Lisbon, Portugal

Learning Objectives:
- Allergen specific immunotherapy in allergic disease management;

- Limitations: adverse events and indication in severe allergic disease

- Immunomodulators, such as omalizumab, as concurrant treatment of specific immunotherapy

See more of: Southern European Allergy Societies (SEAS): Immunotherapy
See more of: Sister Society Symposium
See more of: Symposia
<< Previous Presentation | Next Presentation >>